XTLBNasdaqPharmaceutical Preparations
XTL BIOPHARMACEUTICALS LTD
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Jun 30, 2026
$1.96−0.00 (-0.01%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
XTL BIOPHARMACEUTICALS LTD revenue by segment
By business segment
| Revenue | FY2024 | % of revenue |
|---|---|---|
| Web data collection solutions [Member] | $451.00K | 100.0% |
| Total [Member] | $451.00K | 100.0% |
| Operating income | FY2024 |
|---|---|
| Development of pharmaceutical drugs for the treatment of autoimmune diseases [Member] | -$940.00K |
| Web data collection solutions [Member] | -$1.23M |
| Total [Member] | -$2.17M |
By product or service
By region
From the segment and revenue-disaggregation notes of Xtl Biopharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.